603368 Guangxi LiuYao Group
- 17.27
- +0.08+0.47%
Guangxi LiuYao Group News
Liu Pharmaceutical Group (603368): The three major businesses are gradually improving and accelerating expansion outside the province
Liu Pharmaceutical Group (603368): Distribution business growth is slowing down, waiting for the industry to improve
Liu Pharmaceutical Group (603368): Firmly fulfilling expectations, full-year results are expected to accelerate quarter by quarter
SDIC Securities released a research report on April 28 stating that it gave Liuyao Group (603368.SH) a purchase rating, and the target price was 28.32 yuan. The main reasons for the rating include: 1) Incident: The company released its 2023 annual report
Liuyao Group (603368): Steady growth in wholesale business and accelerated retail and industrial layout are expected to open up room for growth
Liu Pharmaceutical Group (603368): High growth in the industrial sector and continuous improvement in profits in 23 years
Liuyao Group (603368): High net profit growth in 4Q23 is in line with equity incentive targets
Liu Pharmaceutical Group (603368): Guangxi Pharmaceutical Wholesale Leader Diversified Development of Retail Industry Shapes Second Growth Curve
Liu Pharmaceutical Group (603368): Leading regional pharmaceutical distribution, pharmaceutical industry leading cross-regional development
Analysis of the investment value of Liu Yao's debt conversion: the industrial sector is rapidly developing, and both original stock and debt conversion valuations are low
Review of the 2023 Third Quarter Report of Liuyao Group (603368): Steady growth in performance and significant improvement in cash flow
Liuyao Group (603368): Wholesale business maintains steady and rapid industrial business development
Liu Pharmaceutical Group (603368): 3Q profit grew steadily and industrial business continued to expand
Liu Yao Group (603368): Wholesale-side customer stickiness increases, industrial-side marketing results are shown
Liu Pharmaceutical Group (603368): Optimizing the Pharmaceutical Distribution Structure and Rapid Growth of the Pharmaceutical Industry
Liu Pharmaceutical Group (603368): Outstanding industrial business performance in 2Q23
Liuyao Group (603368) In-depth Report: Steady and comprehensive business coverage, leading advantages accelerate development
Liuyao Group (603368): Maintaining a high growth trend in Q1, determined to increase the main business
Liuyao Group (603368): First-quarter results meet expectations and plan to increase 1 billion yuan
Liuyao Group (603368): Net profit increased rapidly year-on-year in 1Q23
No Data
